{"id":32203,"date":"2014-09-26T07:47:54","date_gmt":"2014-09-26T11:47:54","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32203"},"modified":"2014-09-26T07:47:54","modified_gmt":"2014-09-26T11:47:54","slug":"abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203","title":{"rendered":"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 <strong>AbbVie Inc (NYSE:ABBV)<\/strong>\u2019s drug HUMIRA\u00ae (adalimumab) has gained authorization from the U.S. Food and Drug Administration to treat children suffering from Crohn\u2019s disease if they fail to show significant improvements from currently available treatment means.<\/p>\n<p style=\"text-align: justify;\"><strong>Alternative Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">According to PR Newswire <a href=\"http:\/\/www.prnewswire.com\/news-releases\/abbvies-humira-adalimumab-receives-us-fda-approval-for-the-treatment-of-pediatric-patients-with-moderately-to-severely-active-crohns-disease-277054101.html\" target=\"_blank\">news<\/a>, the company announced its latest achievement with HUMIRA yesterday. The FDA has allowed AbbVie Inc (NYSE:ABBV) to use the drug as a treatment option for pediatric patients (6+ years old children) showing symptoms of Crohn\u2019s disease. Patients who have demonstrated moderate or severe conditions of Crohn\u2019s disease and have failed to produce a satisfactory response to immunomodulators or corticosteroids can avail the treatment.<\/p>\n<p style=\"text-align: justify;\">Crohn\u2019s disease is typically an inflammatory bowel disease which is concerned with the end of both the intestines. Although it can occur to people of any age group, it is found to be more common among children and adolescents. In the U.S., as many as 38,000 pediatric patients have been recorded. However, as of now, no cure for the disease exists.<\/p>\n<p style=\"text-align: justify;\">AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA has shown significant success in reducing symptoms and signs of disease. The drug has helped in achieving and maintaining clinical remission. The treatment works by essentially preventing tumor necrosis factor-alpha. It is capable of self-administration after appropriate injection training has been received, in addition to proper guidance of a physician.<\/p>\n<p style=\"text-align: justify;\"><strong>A Milestone Achievement<\/strong><\/p>\n<p style=\"text-align: justify;\">The FDA license represents the eighth indication for the drug adalimumab. It is the first and only biological therapy that can be administered at home to have gained approval for use in children.<\/p>\n<p style=\"text-align: justify;\">HUMIRA had gained approval to be used to treat pediatric patients between age range of 6 and 17 years in the European Union in 2012. The indication was to treat patients suffering from severe and active Crohn\u2019s disease who did not show any improvements with previously available therapies. It was also allowed to cater to children who demonstrated contraindications or were intolerant to conventional treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 AbbVie Inc (NYSE:ABBV)\u2019s drug HUMIRA\u00ae (adalimumab) has gained authorization from the U.S. Food and Drug Administration to treat children suffering [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":21657,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3643,1593,1592],"stock_ticker":[],"class_list":["post-32203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-abbvie-inc","tag-abbvie-inc-nyseabbv","tag-nyseabbv","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 AbbVie Inc (NYSE:ABBV)\u2019s drug HUMIRA\u00ae (adalimumab) has gained authorization from the U.S. Food and Drug Administration to treat children suffering [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-26T11:47:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"456\" \/>\n\t<meta property=\"og:image:height\" content=\"190\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children\",\"datePublished\":\"2014-09-26T11:47:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\"},\"wordCount\":348,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"keywords\":[\"AbbVie Inc\",\"AbbVie Inc. (NYSE:ABBV)\",\"NYSE:ABBV\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\",\"name\":\"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"datePublished\":\"2014-09-26T11:47:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg\",\"width\":456,\"height\":190},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203","og_locale":"en_US","og_type":"article","og_title":"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children  - Wall Street PR","og_description":"Boston, MA 09\/26\/2014 (wallstreetpr) \u2013 AbbVie Inc (NYSE:ABBV)\u2019s drug HUMIRA\u00ae (adalimumab) has gained authorization from the U.S. Food and Drug Administration to treat children suffering [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-26T11:47:54+00:00","og_image":[{"width":456,"height":190,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children","datePublished":"2014-09-26T11:47:54+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203"},"wordCount":348,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","keywords":["AbbVie Inc","AbbVie Inc. (NYSE:ABBV)","NYSE:ABBV"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203","url":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203","name":"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","datePublished":"2014-09-26T11:47:54+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/AbbVie-Inc.-1.jpg","width":456,"height":190},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/abbvie-inc-nyseabbvs-humira-approved-as-first-self-administering-treatment-for-crohns-disease-in-children-32203#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"AbbVie Inc (NYSE:ABBV)\u2019s HUMIRA\u00ae Approved As First Self-Administering Treatment For Crohn\u2019s Disease In Children"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32203"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32203\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/21657"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32203"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}